Survodutide once weekly for the treatment of adults with obesity
le Roux CW, Wharton S, Startseva E, et al.
N Engl J Med. Pub. online 7 Jun 2026.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Lee M. Kaplan, Elena Startseva, Carel W. le Roux
Nat Med. Pub. online 7 Jun 2026.
Leggi
Continuous glucose monitoring and mortality risk among U.S. veterans receiving dialysis with diabetes
Narasaki Y, Kalantar-Zadeh K, Zisman-Ilani Y, et al.
Diabetes Care. Pub. online 1 Jun 2026.
Leggi
Progression to diabetes by adults with prediabetes who use the national diabetes prevention program: a natural experiment
Chorniy A, Owen AL, Kang RH, et al.
Diabetes Care. Pub. online 2 Jun 2026.
Leggi
Continuous glucose monitoring in pregnant women with type 1 diabetes: outcomes of a population-based real-world study
Price SAL, Chee M, Earnest A, et al.
Diabetes Technol Ther. Pub. online 1 Jun 2026.
Leggi
Association of physical activity with all-cause and CVD mortality across metabolic and obesity phenotypes
Han Y, Choi Y, Lee S, Kim YS
Diabetes Obes Metab. Pub. online 28 May 2026.
Leggi
Adding finerenone to SGLT2 inhibitors and long-term kidney outcomes in diabetic kidney disease
Matsui M, Nishimoto M, Kosugi T, et al.
Diabetes Obes Metab. Pub. online 31 May 2026.
Leggi
Impact of sleeve gastrectomy versus intensive lifestyle modifications with obesity management medications on BMI trajectory and target attainment: a prospective matched cohort study
Russo MF, Casella G, Angelini G, et al.
Diabetes Obes Metab. Pub. online 31 May 2026.
Leggi
Efficacy and safety of once-weekly and once-daily basal insulins in type 1 diabetes mellitus: a systematic review and network meta-analysis of clinical trials
Amaral R, Costa B, Penedones A, et al.
Diabetes Obes Metab. Pub. online 1 Jun 2026.
Leggi
Oral semaglutide 25 mg versus orforglipron 36 mg in obesity: a population-adjusted indirect treatment comparison
Michalak W, Bøg M, Bendixen T, et al.
Diabetes Obes Metab. Pub. online 1 Jun 2026.
Leggi